Drug giant AstraZeneca put its clinical trials for a COVID-19 vaccine on hold after one of their study participants suffered an unspecified “serious and unexpected adverse reaction,” the company said.
The trial will be paused while the company conducts a safety review. According to The New York Times:
“A person familiar with the situation, and who spoke on the condition of anonymity, said that the participant had been enrolled in a Phase 2/3 trial based in the United Kingdom. The individual also said that a volunteer in the U.K. trial had been found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.”
How long the safety review will take is unknown.
SOURCE: The New York Times September 9, 2020